<p>Panagora Asset Management Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第一季度将其在阿里拉姆制药公司（NASDAQ:ALNY - 免费报告）的持股增加了 74.5%。该公司在本季度额外购买了 41,340 股后，持有该生物制药公司 96,804 股股票。到最近报告期末，Panagora Asset Management Inc. 持有的阿里拉姆制药公司股份约占 0.07%，价值 26,139,000 美元。</p>
<ul>
<li>阿里拉姆股票飙升 65%：了解背后的原因</li>
</ul>
<p>其他几家对冲基金也买卖了该股票的股份。Orbis Allan Gray Ltd 在第一季度将其在阿里拉姆制药公司的持仓增加了 11.0%。Orbis Allan Gray Ltd 目前持有 1,634,923 股该生物制药公司的股票，价值 441,462,000 美元，此前在上个季度购买了额外的 162,121 股。Vident Advisory LLC 在第一季度将其在阿里拉姆制药公司的持仓增加了 101.0%。Vident Advisory LLC 目前持有 2,667 股该生物制药公司的股票，价值 720,000 美元，此前在上个季度购买了额外的 1,340 股。Kodai Capital Management LP 在第一季度购买了阿里拉姆制药公司的新股份，价值约 5,713,000 美元。Driehaus Capital Management LLC 在第一季度将其在阿里拉姆制药公司的持仓增加了 70.6%。Driehaus Capital Management LLC 目前持有 57,128 股该生物制药公司的股票，价值 15,426,000 美元，此前在上个季度购买了额外的 23,648 股。最后，Iron Triangle Partners LP 在第一季度购买了阿里拉姆制药公司的新股份，价值约 17,662,000 美元。对冲基金和其他机构投资者持有该公司 92.97% 的股票。</p>
<h2>内部人士下注</h2>
<p>在阿里拉姆制药的其他消息中，执行副总裁 Pushkal Garg 于 8 月 19 日星期二出售了 1,455 股该公司的股票。该股票以平均价格 458.41 美元出售，总价值为 666,986.55 美元。出售完成后，该执行副总裁直接持有 20,221 股公司股票，价值 9,269,508.61 美元。这笔交易代表其持仓减少了 6.71%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过此链接查看。此外，执行副总裁 Jeffrey V. Poulton 于 8 月 18 日星期一出售了 2,274 股该公司的股票。该股票以平均价格 453.27 美元出售，总价值为 1,030,735.98 美元。出售完成后，该执行副总裁直接持有 50,121 股公司股票，价值 22,718,345.67 美元。这笔交易代表其持股减少了 4.34%。该出售的披露信息可在此处找到。在过去的九十天里，内部人士出售了价值 31,456,338 美元的 76,891 股公司股票。目前，内部人士持有该股票的 1.50%。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>3 家生物技术巨头在行业反弹中蓄势待发</li>
</ul>
<p>几位股票研究分析师对 ALNY 股票发表了评论。Raymond James Financial 于 7 月 30 日星期三开始对阿里拉姆制药进行覆盖。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 370.00 美元的目标价。摩根士丹利在 8 月 1 日星期五将阿里拉姆制药的目标价从 312.00 美元提高至 405.00 美元，并在研究报告中给予该公司 “持平” 的评级。Oppenheimer 于 8 月 4 日星期一将阿里拉姆制药的评级从 “市场表现” 上调至 “跑赢大盘”，并设定了 490.00 美元的目标价。Scotiabank 于 8 月 1 日星期五将阿里拉姆制药的目标价从 342.00 美元提高至 450.00 美元，并给予该公司 “行业跑赢大盘” 的评级。最后，摩根大通将阿里拉姆制药的目标价从 348.00 美元提高至 475.00 美元，并在 8 月 6 日星期三的研究报告中给予该公司 “增持” 的评级。22 位投资分析师对该股票给予了买入评级，4 位分析师给予了持有评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 405.33 美元。</p>
<p><strong>获取我们关于阿里拉姆制药的最新研究报告</strong></p>
<h2>阿里拉姆制药股价下跌 1.3%</h2>
<ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
<p>阿里拉姆股票在星期五开盘时为 446.51 美元。该股票的 50 日移动平均线为 374.57 美元，200 日移动平均线为 302.99 美元。该公司的债务与股本比率为 4.10，速动比率为 2.75，流动比率为 2.80。该公司的市值为 585.3 亿美元，市盈率为 -180.77，贝塔值为 0.25。阿里拉姆制药公司在过去 52 周的最低价为 205.87 美元，最高价为 469.81 美元。</p>
<p>阿里拉姆制药（NASDAQ:ALNY - 获取免费报告）最近于 7 月 31 日星期四公布了季度财报。该生物制药公司报告本季度每股收益为 0.32 美元，超出分析师的共识预期（-0.54 美元）0.86 美元。阿里拉姆制药的股本回报率为 -273.52%，净利润率为 -12.96%。该公司本季度的收入为 7.7369 亿美元，而分析师预期为 6.3354 亿美元。去年同期，该公司每股收益为 -0.13 美元。该公司本季度的收入同比增长 17.3%。阿里拉姆制药已将其 2025 财年的指导目标设定为每股收益。研究分析师预计阿里拉姆制药公司在当前财年将发布 -1.7 美元的每股收益。</p>
<h2>阿里拉姆制药公司简介</h2>
<p>（免费报告）</p>
<p>阿里拉姆制药公司是一家生物制药公司，专注于基于核糖核酸干扰技术发现、开发和商业化新型治疗药物。其市场产品包括用于治疗成人遗传性转甲状腺素介导的淀粉样变性多发性神经病的 ONPATTRO（patisiran）；用于治疗成人 hATTR 淀粉样变性伴多发性神经病的 AMVUTTRA；用于治疗成人急性肝脏卟啉症的 GIVLAARI；以及用于治疗原发性高草酸尿症 1 型的 OXLUMO。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比阿里拉姆制药更好的股票</li>
<li>为什么股票行业对成功投资很重要？</li>
<li>DICKS 体育用品公司在财报后股价下跌——这是一个买入机会吗？</li>
<li>什么是空头头寸？如何使用它</li>
<li>AI 引擎：康明斯意外的增长动力</li>
<li>如何使用股票筛选器找到股票</li>
<li>小型工业公司看到激增的增长：原因在这里</li>
</ul>
<p><strong>想看看其他对 ALNY 感兴趣的对冲基金持有什么？</strong> 请访问 HoldingsChannel.com 获取阿里拉姆制药公司（NASDAQ:ALNY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在阿里拉姆制药吗？</h2>
<p>在考虑阿里拉姆制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿里拉姆制药并不在名单上。</p>
<p>虽然阿里拉姆制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿里拉姆制药

<p>Panagora Asset Management Inc. 在第一季度将其在阿里拉姆制药（NASDAQ:ALNY）的持股增加了 74.5%，持有 96,804 股，价值 2614 万美元。其他对冲基金也增加了他们的持仓。内部人士最近出售了股票，执行副总裁 Pushkal Garg 出售了 1,455 股，执行副总裁 Jeffrey V. Poulton 出售了 2,274 股。分析师们设定了新的目标价格，摩根士丹利将其目标价格提高至 405.00 美元。该股票开盘价为 446.51 美元，市值为 585.3 亿美元，市场共识目标价格为 405.33 美元</p>

<p>Panagora Asset Management Inc. increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 74.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,804 shares of the biopharmaceutical company's stock after buying an additional 41,340 shares during the quarter. Panagora Asset Management Inc. owned about 0.07% of Alnylam Pharmaceuticals worth $26,139,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Panagora Asset Management Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第一季度将其在阿里拉姆制药公司（NASDAQ:ALNY - 免费报告）的持股增加了 74.5%。该公司在本季度额外购买了 41,340 股后，持有该生物制药公司 96,804 股股票。到最近报告期末，Panagora Asset Management Inc. 持有的阿里拉姆制药公司股份约占 0.07%，价值 26,139,000 美元。</p>
</div><ul>
<li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>阿里拉姆股票飙升 65%：了解背后的原因</li>
</ul>
</div><p>Several other hedge funds have also bought and sold shares of the stock. Orbis Allan Gray Ltd boosted its position in Alnylam Pharmaceuticals by 11.0% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company's stock worth $441,462,000 after purchasing an additional 162,121 shares in the last quarter. Vident Advisory LLC boosted its position in Alnylam Pharmaceuticals by 101.0% in the 1st quarter. Vident Advisory LLC now owns 2,667 shares of the biopharmaceutical company's stock worth $720,000 after purchasing an additional 1,340 shares in the last quarter. Kodai Capital Management LP purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter worth approximately $5,713,000. Driehaus Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 70.6% in the 1st quarter. Driehaus Capital Management LLC now owns 57,128 shares of the biopharmaceutical company's stock worth $15,426,000 after purchasing an additional 23,648 shares in the last quarter. Finally, Iron Triangle Partners LP purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter worth approximately $17,662,000. Hedge funds and other institutional investors own 92.97% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金也买卖了该股票的股份。Orbis Allan Gray Ltd 在第一季度将其在阿里拉姆制药公司的持仓增加了 11.0%。Orbis Allan Gray Ltd 目前持有 1,634,923 股该生物制药公司的股票，价值 441,462,000 美元，此前在上个季度购买了额外的 162,121 股。Vident Advisory LLC 在第一季度将其在阿里拉姆制药公司的持仓增加了 101.0%。Vident Advisory LLC 目前持有 2,667 股该生物制药公司的股票，价值 720,000 美元，此前在上个季度购买了额外的 1,340 股。Kodai Capital Management LP 在第一季度购买了阿里拉姆制药公司的新股份，价值约 5,713,000 美元。Driehaus Capital Management LLC 在第一季度将其在阿里拉姆制药公司的持仓增加了 70.6%。Driehaus Capital Management LLC 目前持有 57,128 股该生物制药公司的股票，价值 15,426,000 美元，此前在上个季度购买了额外的 23,648 股。最后，Iron Triangle Partners LP 在第一季度购买了阿里拉姆制药公司的新股份，价值约 17,662,000 美元。对冲基金和其他机构投资者持有该公司 92.97% 的股票。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of the firm's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the sale, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,269,508.61. This trade represents a 6.71% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the completion of the sale, the executive vice president directly owned 50,121 shares of the company's stock, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,891 shares of company stock worth $31,456,338. 1.50% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在阿里拉姆制药的其他消息中，执行副总裁 Pushkal Garg 于 8 月 19 日星期二出售了 1,455 股该公司的股票。该股票以平均价格 458.41 美元出售，总价值为 666,986.55 美元。出售完成后，该执行副总裁直接持有 20,221 股公司股票，价值 9,269,508.61 美元。这笔交易代表其持仓减少了 6.71%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过此链接查看。此外，执行副总裁 Jeffrey V. Poulton 于 8 月 18 日星期一出售了 2,274 股该公司的股票。该股票以平均价格 453.27 美元出售，总价值为 1,030,735.98 美元。出售完成后，该执行副总裁直接持有 50,121 股公司股票，价值 22,718,345.67 美元。这笔交易代表其持股减少了 4.34%。该出售的披露信息可在此处找到。在过去的九十天里，内部人士出售了价值 31,456,338 美元的 76,891 股公司股票。目前，内部人士持有该股票的 1.50%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>3 biotech powerhouses poised to thrive amid sector rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物技术巨头在行业反弹中蓄势待发</li>
</ul>
</div><p>Several equities research analysts have commented on ALNY shares. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an &#34;outperform&#34; rating and a $370.00 price objective on the stock. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday, August 1st. Oppenheimer upgraded Alnylam Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $490.00 target price on the stock in a research report on Monday, August 4th. Scotiabank increased their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a &#34;sector outperform&#34; rating in a research report on Friday, August 1st. Finally, JPMorgan Chase &amp; Co. increased their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, August 6th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $405.33.</p>
<div class="lb-trans"><p>几位股票研究分析师对 ALNY 股票发表了评论。Raymond James Financial 于 7 月 30 日星期三开始对阿里拉姆制药进行覆盖。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 370.00 美元的目标价。摩根士丹利在 8 月 1 日星期五将阿里拉姆制药的目标价从 312.00 美元提高至 405.00 美元，并在研究报告中给予该公司 “持平” 的评级。Oppenheimer 于 8 月 4 日星期一将阿里拉姆制药的评级从 “市场表现” 上调至 “跑赢大盘”，并设定了 490.00 美元的目标价。Scotiabank 于 8 月 1 日星期五将阿里拉姆制药的目标价从 342.00 美元提高至 450.00 美元，并给予该公司 “行业跑赢大盘” 的评级。最后，摩根大通将阿里拉姆制药的目标价从 348.00 美元提高至 475.00 美元，并在 8 月 6 日星期三的研究报告中给予该公司 “增持” 的评级。22 位投资分析师对该股票给予了买入评级，4 位分析师给予了持有评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 405.33 美元。</p>
</div><p><strong>Get Our Latest Research Report on Alnylam Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于阿里拉姆制药的最新研究报告</strong></p>
</div><h2>Alnylam Pharmaceuticals Trading Down 1.3%</h2>
<div class="lb-trans"><h2>阿里拉姆制药股价下跌 1.3%</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>Shares of ALNY stock opened at $446.51 on Friday. The stock's fifty day moving average is $374.57 and its two-hundred day moving average is $302.99. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market capitalization of $58.53 billion, a P/E ratio of -180.77 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $469.81.</p>
<div class="lb-trans"><p>阿里拉姆股票在星期五开盘时为 446.51 美元。该股票的 50 日移动平均线为 374.57 美元，200 日移动平均线为 302.99 美元。该公司的债务与股本比率为 4.10，速动比率为 2.75，流动比率为 2.80。该公司的市值为 585.3 亿美元，市盈率为 -180.77，贝塔值为 0.25。阿里拉姆制药公司在过去 52 周的最低价为 205.87 美元，最高价为 469.81 美元。</p>
</div><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same quarter last year, the firm posted ($0.13) EPS. The firm's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>阿里拉姆制药（NASDAQ:ALNY - 获取免费报告）最近于 7 月 31 日星期四公布了季度财报。该生物制药公司报告本季度每股收益为 0.32 美元，超出分析师的共识预期（-0.54 美元）0.86 美元。阿里拉姆制药的股本回报率为 -273.52%，净利润率为 -12.96%。该公司本季度的收入为 7.7369 亿美元，而分析师预期为 6.3354 亿美元。去年同期，该公司每股收益为 -0.13 美元。该公司本季度的收入同比增长 17.3%。阿里拉姆制药已将其 2025 财年的指导目标设定为每股收益。研究分析师预计阿里拉姆制药公司在当前财年将发布 -1.7 美元的每股收益。</p>
</div><h2>Alnylam Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>阿里拉姆制药公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.</p>
<div class="lb-trans"><p>阿里拉姆制药公司是一家生物制药公司，专注于基于核糖核酸干扰技术发现、开发和商业化新型治疗药物。其市场产品包括用于治疗成人遗传性转甲状腺素介导的淀粉样变性多发性神经病的 ONPATTRO（patisiran）；用于治疗成人 hATTR 淀粉样变性伴多发性神经病的 AMVUTTRA；用于治疗成人急性肝脏卟啉症的 GIVLAARI；以及用于治疗原发性高草酸尿症 1 型的 OXLUMO。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Alnylam Pharmaceuticals</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?</li>
<li>What is Short Interest? How to Use It</li>
<li>Engines to AI: Cummins’ Surprising Growth Driver</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Smaller Industrials Names Seeing Surging Growth: Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比阿里拉姆制药更好的股票</li>
<li>为什么股票行业对成功投资很重要？</li>
<li>DICKS 体育用品公司在财报后股价下跌——这是一个买入机会吗？</li>
<li>什么是空头头寸？如何使用它</li>
<li>AI 引擎：康明斯意外的增长动力</li>
<li>如何使用股票筛选器找到股票</li>
<li>小型工业公司看到激增的增长：原因在这里</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ALNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ALNY 感兴趣的对冲基金持有什么？</strong> 请访问 HoldingsChannel.com 获取阿里拉姆制药公司（NASDAQ:ALNY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ALNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在阿里拉姆制药吗？</h2>
</div><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿里拉姆制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿里拉姆制药并不在名单上。</p>
</div><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿里拉姆制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿里拉姆制药公司 $ALNY 的股票被 Panagora 资产管理公司购入